ClinicalTrials.gg
RecruitingNCT05258292GLYMETYUpdated Mar 5, 2026

Glycemic Variations During the Menstrual Cycle in Women With Type 1 Diabetes

An observational study in Type1diabetes, sponsored by Institut de Recherches Cliniques de Montreal. Recruiting at 1 site in Canada. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by Institut de Recherches Cliniques de Montreal · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started May 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
86
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 705 studies in Motor Activity with a site in Canada — 135 open to participants now, 165 under way, 2 of them phase 3. Motor Activity · Canada.

Planned enrollment
15th of 42
86 · median 50
Started
2022
with 42 others
Observational
42 of 705
10 open now
Primary completion
2026-04
later than 59 of 164 live
Registered
516th of 705
by date

Among the 705 studies in Motor Activity with a site in Canada, this one is the 15th largest by planned enrollment of the 42 observational ones that give a count, is one of 43 that started in 2022, is one of 42 observational ones, reaches primary completion later than 59 of the 164 other live ones, and was the 516th registered.

Motor Activity

9,827 studies on the registry are indexed under Motor Activity; 1,911 are open to participants now.

Browse Motor Activity studies →

Open to participants now

135 of the 705 studies in Motor Activity with a site in Canada are open now. Recruiting first, the newest first:

130 more — sign in →

All 135 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 1,207 Motor Activity studies recruiting now, 524 (43%) set no upper age limit and 538 (45%) stop at 75 or younger; 180 take children under 18; 420 take healthy volunteers.

This study: 18 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 705 studies in Motor Activity with a site in Canada, or all of them as a file.
02

Study summary

In clinical practice, women living with type 1 diabetes frequently report that insulin requirements change across the menstrual cycle. Consequently, glycemic fluctuations are observed. This phenomenon could be explained by a decrease in insulin sensitivity during the second half of the menstrual cycle (luteal phase).

Overall, despite an important proportion of women reporting glycemic and/or insulin variations across the menstrual cycle, studies to date have involved small sample sizes, and have had inconsistent results. The objective of this study will be to study glycemic fluctuations across the menstrual cycle using CGM data, alongside insulin data, in a large sample of women.

03

Conditions studied

  • Type1diabetes

Browse trials for

Keywords

  • Menstrual cycle
  • Continuous glucose monitoring
  • Insulin dose
  • Physical activity
  • Food intake
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women aged 18 to 50 living with type 1 diabetes.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Females aged 18 to 50 living in Canada.
  2. Clinical diagnosis of type 1 diabetes or latent diabetes in adults (LADA) for at least one year.
  3. Using insulin pump therapy, multiple daily injections or automated insulin delivery systems for at least 3 months.
  4. Using a continuous glucose monitoring (CGM) system.
  5. Having at least one menses in the last 40 days.
  6. Accepting to share CGM data with the research team and if applicable insulin pump data.This access will be limited to the study period.
  7. Having a smartphone or tablet to follow menstrual cycles.
  8. Stable weight (less than 5% variation in the last 3 months).

Exclusion criteria

Exclusion Criteria:

  1. Using a hormonal method that eliminates menses (Depo Provera, progestin intrauterine device, extented-cycle regimen with birth control pill)
  2. Using regular insulin (Entuzity U500, Novolin ge Toronto or Humulin R).
  3. nephropathy ( \< 30 ml/min/1.73m2, planned or on dialysis) or neuropathy (e.g., known uncontrolled gastroparesis) as judged by the investigator.
  4. Recent (\< 6 months) acute macrovascular event (e.g., acute coronary syndrome or cardiac surgery).
  5. Anticipated therapeutic change (including change of insulin type and/or type of CGM sensor, insulin pump or AID (automated insulin device) system) between admission and end of the study.
  6. Anticipated change in contraception method or plan to begin or stop a contraceptive method.
  7. Anticipated need to use acetaminophen during the study period at a dose above 1g every 6 hours.
  8. Pregnancy (ongoing or current attempt to become pregnant)
  9. Breastfeeding
  10. Uncontrolled thyroid disease (TSH should be in target range and treatment stable for at least 6 weeks).
  11. Severe hypoglycemic episode within two weeks of screening
  12. Severe hyperglycemic episodes requiring hospitalization in the last 3 months.
  13. Current use of medication (except low stable dose and inhaled steroids and stable adrenal insufficiency treatment e.g., Cortef®)
  14. Agents affecting gastric emptying (Motilium®, Victoza®, Ozempic®, Trulicity®, Byetta® and Symlin®) as well as oral anti-diabetic agents (Metformin, Prandase®, DPP-4 inhibitors) unless at a stable dose for 3 months and without anticipated change during the study.
  15. Current use of SGLT-2 inhibitors unless at a stable dose for at least 3 months, without anticipated change during the study and appropriate ketone testing is performed.
  16. Other serious medical illnesses which likely interfere with study participation or with the ability to complete the study by the judgment of the investigator.
  17. Anticipation of a significant change in exercise or diet regimen between admission and end of the study (i.e., starting or stopping an organized sport; planned significant diet change).
  18. Anticipated radiologic examination incompatible with CGM wear for more than 10 days between admission and end of the study (e.g., repeated MRI).
  19. In the opinion of the investigator, a participant who is unable or unwilling to complete the study.
  20. If taking medication for hypothyroidism, no change of dose (Levothyroxin) in the last 6 weeks.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
86 participants (estimated)
Patient registry
No

Groups and cohorts

  • Women with type 1 diabetes

    Device: Continuous glucose monitoring · Drug: Insulin · Other: Premenstrual symptoms · Other: Ovulation kits · Device: Fitbit Inspire 2 · Other: Keenoa · Other: Menstrual cycle

Interventions

  • DeviceContinuous glucose monitoring

    Glucose levels will be measured using continuous glucose monitoring

  • Insulin doses will be retrieved from insulin pump reports (for insulin pump users) or journals for (for multiple daily injections users)

  • OtherPremenstrual symptoms

    Premenstrual symptoms will be assessed using the Premenstrual symptoms screening tool

  • OtherOvulation kits

    Ovulation testing will be done using ovulation kits

  • DeviceFitbit Inspire 2

    Physical activity will be assessed using the Fitbit Inspire 2

  • OtherKeenoa

    Food intake will be assessed using the Keenoa phone application

  • OtherMenstrual cycle

    The application My Calendar will be used to record information on the menstrual cycle

06

What researchers measure

Primary outcomes

  1. Mean glucose levels during the early follicular phase

    Time frame: Day 1 to 5 of the menstrual cycle

  2. Mean glucose levels during the mid-late follicular phase

    Time frame: Day 6 until 2 days prior to ovulation

  3. Mean glucose levels during the periovulation phase

    Time frame: Ovulation plus/minus 1 day

  4. Mean glucose levels during the early luteal phase

    Time frame: Day 2 to 4 after ovulation

  5. Mean glucose levels during the mid-luteal phase

    Time frame: Day 5 to 9 after ovulation

  6. Mean glucose levels during the late luteal phase

    Time frame: Day 10 after ovulation until the first day of the next menstrual cycle

Secondary outcomes

  1. Percentage of time of glucose levels between 3.9 and 7.8 mmol/L

    Time frame: Day 1 to 5 of the menstrual cycle

  2. Percentage of time of glucose levels between 3.9 and 7.8 mmol/L

    Time frame: Day 6 until 2 days prior to ovulation

  3. Percentage of time of glucose levels between 3.9 and 7.8 mmol/L

    Time frame: Ovulation plus/minus 1 day

  4. Percentage of time of glucose levels between 3.9 and 7.8 mmol/L

    Time frame: Day 2 to 4 after ovulation

  5. Percentage of time of glucose levels between 3.9 and 7.8 mmol/L

    Time frame: Day 5 to 9 after ovulation

  6. Percentage of time of glucose levels between 3.9 and 7.8 mmol/L

    Time frame: Day 10 after ovulation until the first day of the next menstrual cycle

  7. Percentage of time of glucose levels between 3.9 and 10.0 mmol/L

    Time frame: Day 1 to 5 of the menstrual cycle

  8. Percentage of time of glucose levels between 3.9 and 10.0 mmol/L

    Time frame: Day 6 until 2 days prior to ovulation

  9. Percentage of time of glucose levels between 3.9 and 10.0 mmol/L

    Time frame: Ovulation plus/minus 1 day

  10. Percentage of time of glucose levels between 3.9 and 10.0 mmol/L

    Time frame: Day 2 to 4 after ovulation

  11. Percentage of time of glucose levels between 3.9 and 10.0 mmol/L

    Time frame: Day 5 to 9 after ovulation

  12. Percentage of time of glucose levels between 3.9 and 10.0 mmol/L

    Time frame: Day 10 after ovulation until the first day of the next menstrual cycle

  13. Percentage of time of glucose levels below 3.9 mmol/L

    Time frame: Day 1 to 5 of the menstrual cycle

  14. Percentage of time of glucose levels below 3.9 mmol/L

    Time frame: Day 6 until 2 days prior to ovulation

  15. Percentage of time of glucose levels below 3.9 mmol/L

    Time frame: Ovulation plus/minus 1 day

  16. Percentage of time of glucose levels below 3.9 mmol/L

    Time frame: Day 2 to 4 after ovulation

  17. Percentage of time of glucose levels below 3.9 mmol/L

    Time frame: Day 5 to 9 after ovulation

  18. Percentage of time of glucose levels below 3.9 mmol/L

    Time frame: Day 10 after ovulation until the first day of the next menstrual cycle

  19. Percentage of time of glucose levels below 3.0 mmol/L

    Time frame: Day 1 to 5 of the menstrual cycle

  20. Percentage of time of glucose levels below 3.0 mmol/L

    Time frame: Day 6 until 2 days prior to ovulation

  21. Percentage of time of glucose levels below 3.0 mmol/L

    Time frame: Ovulation plus/minus 1 day

  22. Percentage of time of glucose levels below 3.0 mmol/L

    Time frame: Day 2 to 4 after ovulation

  23. Percentage of time of glucose levels below 3.0 mmol/L

    Time frame: Day 5 to 9 after ovulation

  24. Percentage of time of glucose levels below 3.0 mmol/L

    Time frame: Day 10 after ovulation until the first day of the next menstrual cycle

  25. Percentage of time of glucose levels above 10.0 mmol/L

    Time frame: Day 1 to 5 of the menstrual cycle

  26. Percentage of time of glucose levels above 10.0 mmol/L

    Time frame: Day 6 until 2 days prior to ovulation

  27. Percentage of time of glucose levels above 10.0 mmol/L

    Time frame: Ovulation plus/minus 1 day

  28. Percentage of time of glucose levels above 10.0 mmol/L

    Time frame: Day 2 to 4 after ovulation

  29. Percentage of time of glucose levels above 10.0 mmol/L

    Time frame: Day 5 to 9 after ovulation

  30. Percentage of time of glucose levels above 10.0 mmol/L

    Time frame: Day 10 after ovulation until the first day of the next menstrual cycle

  31. Percentage of time of glucose levels above 13.9 mmol/L

    Time frame: Day 1 to 5 of the menstrual cycle

  32. Percentage of time of glucose levels above 13.9 mmol/L

    Time frame: Day 6 until 2 days prior to ovulation

  33. Percentage of time of glucose levels above 13.9 mmol/L

    Time frame: Ovulation plus/minus 1 day

  34. Percentage of time of glucose levels above 13.9 mmol/L

    Time frame: Day 2 to 4 after ovulation

  35. Percentage of time of glucose levels above 13.9 mmol/L

    Time frame: Day 5 to 9 after ovulation

  36. Percentage of time of glucose levels above 13.9 mmol/L

    Time frame: Day 10 after ovulation until the first day of the next menstrual cycle

  37. Standard deviation of glucose levels

    Time frame: Day 1 to 5 of the menstrual cycle

  38. Standard deviation of glucose levels

    Time frame: Day 6 until 2 days prior to ovulation

  39. Standard deviation of glucose levels

    Time frame: Ovulation plus/minus 1 day

  40. Standard deviation of glucose levels

    Time frame: Day 2 to 4 after ovulation

  41. Standard deviation of glucose levels

    Time frame: Day 5 to 9 after ovulation

  42. Standard deviation of glucose levels

    Time frame: Day 10 after ovulation until the first day of the next menstrual cycle

  43. Coefficient of variance of glucose levels

    Time frame: Day 1 to 5 of the menstrual cycle

  44. Coefficient of variance of glucose levels

    Time frame: Day 6 until 2 days prior to ovulation

  45. Coefficient of variance of glucose levels

    Time frame: Ovulation plus/minus 1 day

  46. Coefficient of variance of glucose levels

    Time frame: Day 2 to 4 after ovulation

  47. Coefficient of variance of glucose levels

    Time frame: Day 5 to 9 after ovulation

  48. Coefficient of variance of glucose levels

    Time frame: Day 10 after ovulation until the first day of the next menstrual cycle

  49. Low blood glucose index

    Time frame: Day 1 to 5 of the menstrual cycle

  50. Low blood glucose index

    Time frame: Day 6 until 2 days prior to ovulation

  51. Low blood glucose index

    Time frame: Ovulation plus/minus 1 day

  52. Low blood glucose index

    Time frame: Day 2 to 4 after ovulation

  53. Low blood glucose index

    Time frame: Day 5 to 9 after ovulation

  54. Low blood glucose index

    Time frame: Day 10 after ovulation until the first day of the next menstrual cycle

  55. High blood glucose index

    Time frame: Day 1 to 5 of the menstrual cycle

  56. High blood glucose index

    Time frame: Day 6 until 2 days prior to ovulation

  57. High blood glucose index

    Time frame: Ovulation plus/minus 1 day

  58. High blood glucose index

    Time frame: Day 2 to 4 after ovulation

  59. High blood glucose index

    Time frame: Day 5 to 9 after ovulation

  60. High blood glucose index

    Time frame: Day 10 after ovulation until the first day of the next menstrual cycle

  61. Standard deviation of insulin delivery

    Time frame: Day 1 to 5 of the menstrual cycle

  62. Standard deviation of insulin delivery

    Time frame: Day 6 until 2 days prior to ovulation

  63. Standard deviation of insulin delivery

    Time frame: Ovulation plus/minus 1 day

  64. Standard deviation of insulin delivery

    Time frame: Day 2 to 4 after ovulation

  65. Standard deviation of insulin delivery

    Time frame: Day 5 to 9 after ovulation

  66. Standard deviation of insulin delivery

    Time frame: Day 10 after ovulation until the first day of the next menstrual cycle

  67. Coefficient of variance of insulin delivery

    Time frame: Day 1 to 5 of the menstrual cycle

  68. Coefficient of variance of insulin delivery

    Time frame: Day 6 until 2 days prior to ovulation

  69. Coefficient of variance of insulin delivery

    Time frame: Ovulation plus/minus 1 day

  70. Coefficient of variance of insulin delivery

    Time frame: Day 2 to 4 after ovulation

  71. Coefficient of variance of insulin delivery

    Time frame: Day 5 to 9 after ovulation

  72. Coefficient of variance of insulin delivery

    Time frame: Day 10 after ovulation until the first day of the next menstrual cycle

  73. Total insulin delivery

    Time frame: Day 1 to 5 of the menstrual cycle

  74. Total insulin delivery

    Time frame: Day 6 until 2 days prior to ovulation

  75. Total insulin delivery

    Time frame: Ovulation plus/minus 1 day

  76. Total insulin delivery

    Time frame: Day 2 to 4 after ovulation

  77. Total insulin delivery

    Time frame: Day 5 to 9 after ovulation

  78. Total insulin delivery

    Time frame: Day 10 after ovulation until the first day of the next menstrual cycle

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Apr 2026, 46 months after the start.

Of 492 non-industry observational studies under Motor Activity, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 48. This study's planned 46 months is above that.

Counting every sponsor, half of 502 studies reached it within 22 months; a quarter within 8 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2022
First posted
Feb 28, 2022
StartActual
May 2, 2022
Primary completionEst.
Apr 1, 2026
CompletionEst.
May 31, 2026
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05258292
Lead sponsor
Institut de Recherches Cliniques de Montreal
Responsible party
Rémi Rabasa-Lhoret (Full professor, Institut de Recherches Cliniques de Montreal) — Principal investigator
First posted
Feb 28, 2022
Start date
May 2, 2022
Primary completion
Apr 1, 2026 (estimated)
Completion
May 31, 2026 (estimated)
Last update
Mar 5, 2026

Study contacts

Anne Bonhoure
Contact
anne.bonhoure@ircm.qc.ca
514-987-5500 ext. 3238
Rémi Rabasa-Lhoret
principal investigator · Institut de Recherches Cliniques de Montreal

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion